Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential mitomycin + BCG vs BCG alone in high-risk non-muscle invasive bladder cancer
2017-004540-37Phase 4Active
- Sponsor
- Sant'Andrea Hospital
- Start
- Sep 2021
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in bladder cancer comparing Sequential mitomycin + BCG with BCG monotherapy (2 arms). Primary endpoint: Recurrence rate. Started Sep 2021; status: active.
02
Drugs
mitomycin cbcg vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2017-004540-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004540-37.